Mitochondrial checkpoint for interferon responses in macrophages

Abstract

A functional immune system is a key antagonist of cancer cell growth. Cytokines such as interferons (IFNs) promote the onset of inflammation, turn cells into an anti-viral state, and shape the dynamic tumor-immune cell interactome. Recent work illustrates how type I IFNs contribute to the resolution of inflammatory conditions. This involves macrophage-mediated efferocytosis for the clearance of apoptotic cells and the intrinsic capacity of type I IFNs to restrict their own autocrine signaling loops via the IFN-stimulated gene 15 (ISG15) protein. We discuss how this may affect tumor cells and how acetylation-dependent processes can affect the phosphorylation-dependent signaling cascades that augment IFN-dependent gene expression.

Keywords

acetylation / efferocytosis / histone deacetylase (HDAC) / JAK-STAT / gene expression / interferon / ISG15 / macrophage

References

[1] Stienstra R, Netea-Maier RT, Riksen NP, Joosten LAB, Netea MG. Specific and Complex Reprogramming of Cellular Metabolism in Myeloid Cells during Innate Immune Responses. Cell Metab. 2017; 26: 142-56.

[2] Al-Horani RA. Cancer Metabolism and Its Historical & Molecular Foundations: An Overview. Drugs Drug Candidates. 2026; 5: 17.

[3] Dunphy G, Adán-Barrientos I, Fernández-Delgado I, Villarroya-Beltri C, Heras-Murillo I, Moya-Ruiz E, et al. A type I interferon-mitochondrial axis regulates efferocytosis and interferon-stimulated gene induction in macrophages. Immunity. 2026; 59: 306-21.e7.

[4] Krieg AM. New insights into the role of IFN-α/β and TLR7/8/9 in cancer immunotherapy and systemic autoimmunity. J ImmunoTher Cancer. 2025; 13: e012165.

[5] Kasat D, Hidalgo S, Wang L, Bui JD, Dosset M. Interferons as therapeutic orchestrators of cancer stem cell plasticity and therapy response. Cytokine Growth Factor Rev. 2026; 87: 102-12.

[6] Tecalco-Cruz AC, Zepeda-Cervantes J. Protein ISGylation: a posttranslational modification with implications for malignant neoplasms. Explor Target Antitumor Ther. 2023; 4: 699-715.

[7] Feng X, Qiao Y, Cui S. When ISG15 is involved in inflammation. Front Immunol. 2026; 17: 1775143.

[8] Yuan Y, Qin H, Li H, Shi W, Bao L, Xu S, et al. The Functional Roles of ISG15/ISGylation in Cancer. Molecules. 2023; 28: 1337.

[9] Gupta AK, Wu J, Das P, Sharma R, Das S, Han K, et al. ISG15 orchestrates dynamic crosstalk between mitochondrial fat oxidation and type 1 interferon in myeloid cells. bioRxiv 2026.01.19.700051 [Preprint]. 2026 [cited 2026 Mar 19]. Available from: https://doi.org/10.64898/2026.01.19.700051

[10] Quan Q, Wu N, Luo YH, Tang YJ, Liu YZ, Huang XC, et al. Global Transmission, Prevention, Control, and Treatment of Mpox Virus in 2025: A Comprehensive Review from Infection Mechanisms to Vaccine Development. Vaccines. 2025; 13: 1071.

[11] Wang X, Shi X, Liao S, Su T, Gu Y, Zhang H, et al. Multidimensional effects of genetic mechanisms in cancer occurrence, development and treatment. Cancer Genet. 2026; 304-305: 58-75.

[12] Haikarainen T, Virtanen AT, Cravatt BF, Silvennoinen O. Pharmacological targeting of the JAK-STAT pathway: new concepts and emerging indications. Nat Rev Drug Discov. 2026; 25: 268-89.

[13] Mustafa AM, Krämer OH. Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer. Pharmacol Rev. 2023; 75: 35-61.

[14] Baldanta S, Fernández-Escobar M, Acín-Perez R, Albert M, Camafeita E, Jorge I, et al. ISG15 governs mitochondrial function in macrophages following vaccinia virus infection. PLOS Pathog. 2017; 13: e1006651.

[15] Palma FR, Gantner BN, Sakiyama MJ, Kayzuka C, Shukla S, Lacchini R, et al. ROS production by mitochondria: function or dysfunction? Oncogene. 2023; 43: 295-303.

[16] Guerra S, Cáceres A, Knobeloch KP, Horak I, Esteban M. Vaccinia Virus E3 Protein Prevents the Antiviral Action of ISG15. PLoS Pathog. 2008; 4: e1000096.

[17] Bécares M, Albert M, Tárrega C, Coloma R, Falqui M, Luhmann EK, et al. ISG15 Is Required for the Dissemination of Vaccinia Virus Extracellular Virions. Microbiol Spectr. 2023; 11: e0450822.

[18] Zhao C, Sridharan H, Chen R, Baker DP, Wang S, Krug RM. Influenza B virus non-structural protein 1 counteracts ISG15 antiviral activity by sequestering ISGylated viral proteins. Nat Commun. 2016; 7: 12754.

[19] Yu SS, Tang RC, Zhang A, Geng S, Yu H, Zhang Y, et al. Deacetylase Sirtuin 1 mitigates type I IFN-and type II IFN-induced signaling and antiviral immunity. J Virol. 2024; 98: e0008824.

[20] Hansen BK, Gupta R, Baldus L, Lyon D, Narita T, Lammers M, et al. Analysis of human acetylation stoichiometry defines mechanistic constraints on protein regulation. Nat Commun. 2019; 10: 1055.

[21] Mustafa AM, Petrosino G, Fischer MA, Schnöder TM, Gül D, Zeyn Y, et al. The deacetylases HDAC1/HDAC2 control JAK2V617F-STAT signaling through the ubiquitin ligase SIAH2. Signal Transduct Target Ther. 2025; 10: 275.

[22] Tigu AB, Ivancuta A, Uhl A, Sabo AC, Nistor M, Mureșan XM, et al. Epigenetic Therapies in Melanoma-Targeting DNA Methylation and Histone Modification. Biomedicines. 2025; 13: 1188.

[23] Mazziotta C, Lanzillotti C, Gafà R, Touzé A, Durand MA, Martini F, et al. The Role of Histone Post-Translational Modifications in Merkel Cell Carcinoma. Front Oncol. 2022; 12: 832047.

[24] Ma Y, Kemp SS, Yang X, Wu MH, Yuan SY. Cellular mechanisms underlying the impairment of macrophage efferocytosis. Immunol Lett. 2023; 254: 41-53.

[25] Dawson A, Zarou MM, Prasad B, Bittencourt-Silvestre J, Zerbst D, Himonas E, et al. Leukaemia exposure alters the transcriptional profile and function of BCR:ABL1 negative macrophages in the bone marrow niche. Nat Commun. 2024; 15: 1090.

[26] Cruz Cruz J, Allison KC, Page LS, Jenkins AJ, Wang X, Earp HS, et al. Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment. Front Immunol. 2023; 14: 1146721.

[27] Zhong F, Yao F, Bai Q, Liu J, Li X, Huang B, et al. A novel molecular classification based on efferocytosis-related genes for predicting clinical outcome and treatment response in acute myeloid leukemia. Inflamm Res. 2024; 73: 1889-902.

[28] Fan JB, Miyauchi-Ishida S, Arimoto K, Liu D, Yan M, Liu CW, et al. Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation. Proc Natl Acad Sci. 2015; 112: 14313-8.

[29] Malik MNH, Waqas SF, Zeitvogel J, Cheng J, Geffers R, Gouda ZA, et al. Congenital deficiency reveals critical role of ISG15 in skin homeostasis. J Clin Investig. 2022; 132: e132.

[30] Zhao C, Collins MN, Hsiang TY, Krug RM. Interferon-induced ISG15 pathway: an ongoing virus-host battle. Trends Microbiol. 2013; 21: 181-6.

[31] Pölönen P, Mehtonen J, Lin J, Liuksiala T, Häyrynen S, Teppo S, et al. Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies. Cancer Res. 2019; 15: 2466-79.